POS1488 LUPUS DAMAGE INDEX REVISION – INITIAL ITEM REDUCTION PHASE

Background An international initiative is underway to develop a revised systemic lupus erythematosus (SLE) organ damage index (SDI) using multi-phase process that supported by the SLE International Collaborating Clinics (SLICC), American College of Rheumatology (ACR) and Lupus Foundation America (LFA). The first two phases (evaluating construct item generation through literature review an Delphi exercise) were previously reported [1,2] , 220 candidate items generated. Objectives To report initial reduction phase results five-phase for developing SDI. Methods two-part exercise asked experts patients rate how appropriate they inclusion in SDI on 9-point Likert scale (where 1 = not at all 9 completely appropriate) considering new [1] . definitions plain English provided patient representatives. In part round, participants suggest any additional items. subsequent presented their own rating, median scores 25 th -75 percentiles each item. They given opportunity revise rating. Items with ratings less than or equal 4.0/ 9.0 considered removal. Results A total 143 out 146 who completed round invited rounds. Completion rates second third rounds 95% 91.7% respectively. Appropriateness rating included full range scoring possibilities from 9. Participants suggested 53 potentially items, however only 6 retained, as others duplicates invalid. 226 re-rate appropriateness. There was stability terms summary Thirty-six had score 4. Figure shows number identified different stages project. All original retained group appropriateness 7, 8 9; exceptions upper gastrointestinal tract surgery (median 5) osteomyelitis 5). Conclusion methods reduced consideration. 1996 [3] this step. Further steps are now refine rationalize list. References [1]Johnson, S. R et al. (2021). Evaluating SLE. Arthritis Care Res. [2]Kundakci, B. (2022). Systemic Erythematosus (ACR), (LFA) Damage Index Revision - Item Generation Phase [abstract]. Rheumatol. Gladman D. (1996). development validation SLICC/ACR Acknowledgements We thank collaborators valuable input. project LFA, SLICC ACR. Disclosure Interests Burak Kundakci: None declared, Megan Barber Consultant of: AbbVie, AstraZeneca, GSK, Janssen, Sanofi-Genzyme, Ann E Clarke Speakers bureau: BMS, Grant/research support from: Sindhu Johnson: Ian N. Bruce Astra Zeneca, Janssen. Aurinia, Lilly.